Varenicline: cardiovascular safety
نویسندگان
چکیده
منابع مشابه
Evaluation of the cardiovascular effects of varenicline in rats
BACKGROUND Cardiovascular disease is an important cause of morbidity and mortality among tobacco users. Varenicline is widely used worldwide to help smoking cessation, but some published studies have reported associated cardiovascular events. OBJECTIVE To determine the cardiovascular toxicity induced by varenicline in rats. MATERIALS AND METHODS We randomly separated 34 rats into two groups...
متن کاملCardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study
BACKGROUND Varenicline is an effective pharmacotherapy to aid smoking cessation. However, its use is limited by continuing concerns about possible associated risks of serious adverse cardiovascular and neuropsychiatric events. The aim of this study was to investigate whether use of varenicline is associated with such events. METHODS In this retrospective cohort study, we used data from patien...
متن کاملVarenicline for smoking cessation: efficacy, safety, and treatment recommendations
Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is eff...
متن کاملEpidemiology and Prevention Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease A Randomized Trial
Background—Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial 4 2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown. Methods and Results—A multicenter, randomized, double-blind, placebo-controlled trial compared th...
متن کاملCardiovascular safety of NSAIDs.
Evidence • Meta-analysis of 754 RCTs (about 350 000 patients)1: -Mixed population, primarily patients with arthritis at low to moderate CV risk (ie, CV event rate about 1% per year). -Use of COX-2 inhibitors compared with placebo increased —all-cause mortality, rate ratio (RR) = 1.22 (95% CI 1.04 to 1.44); and —serious CV events, RR = 1.37 (95% CI 1.14 to 1.66). -Diclofenac (150 mg daily): simi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Medical Association Journal
سال: 2011
ISSN: 0820-3946,1488-2329
DOI: 10.1503/cmaj.111-2073